6-甲基-4,5-庚二烯-1-胺 | 138808-37-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 6-甲基-4,5-庚二烯-1-胺
• 英文名称: 6-methyl-heptanenitrile
• 英文别名: 6-Methyl-heptannitril；6-Methylheptanenitrile
• CAS: 138808-37-4
• 化学式: C₈H₁₅N
• 分子量: 125.214
• InChiKey: DRHROSXFXTXWKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-甲基-4,5-庚二烯-1-胺 在 乙醇 、 sodium 作用下， 生成 1-氨基-6-甲基庚
  参考文献：
  名称：

  Clarke, Journal of the Chemical Society, 1913, vol. 103, p. 1699

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 phosphorus pentoxide 作用下， 生成 6-甲基-4,5-庚二烯-1-胺
  参考文献：
  名称：

  Clarke, Journal of the Chemical Society, 1913, vol. 103, p. 1699

  摘要：

  DOI：

文献信息

• COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：Liu Yi

  公开号：US20140357651A1

  公开（公告）日：2014-12-04

  The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.

  本发明提供了用于治疗增殖性疾病的方法和药物组合物。在一个方面，该方法包括给予具有协同作用的两种细胞周期抑制剂。在另一个方面，一种药物组合物中提供了具有协同作用的两种细胞周期抑制剂。
• BENZIMIDAZOLONE DERIVATIVES
  申请人：Ando Kazuo

  公开号：US20090298811A1

  公开（公告）日：2009-12-03

  This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) or pharmaceutically acceptable salts thereof, wherein: A, B, R 1 , R 2 and R 3 are each as described herein. These compounds are useful in the treatment of a condition mediated by CB2 receptor binding activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, spasticity, epilepsy, Tourette's syndrome, Parkinson's disease, neuroprotection, anxiety, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, cachexia, nausea, emesis, chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, gastroesophageal reflux disease (GERD), constipation, diarrhea, functional gastrointestinal disorder, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasodialation, hypertension, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, chronic obstructive pulmonary disease (COPD), cryptogenic fibrosing alveolitis and bronchitis.

  本发明涉及化合物和方法，用于治疗由CB1受体活性在哺乳动物主体中介导的疾病，包括人类，其包括向需要该治疗的哺乳动物施用化合物的治疗有效量的公式(I)或其药用可接受盐，其中：A、B、R1、R2和R3如本文所述。这些化合物在治疗由CB2受体结合活性介导的疾病中有用，如但不限于炎症性疼痛、伤害性疼痛、神经性疼痛、纤维肌痛、慢性腰痛、内脏疼痛、急性脑缺血、疼痛、慢性疼痛、急性疼痛、带状疱疹后神经痛、神经病、神经痛、糖尿病性神经病、艾滋病相关神经病、神经损伤、类风湿性关节炎疼痛、骨关节炎疼痛、背部疼痛、癌症疼痛、牙痛、纤维肌痛、神经炎、坐骨神经痛、炎症、神经退行性疾病、痉挛、癫痫、托瑞特综合征、帕金森病、神经保护、焦虑、咳嗽、支气管痉挛、肠易激综合征（IBS）、炎症性肠病（IBD）、结肠炎、脑血管缺血、虚弱、恶心、呕吐、化疗诱导呕吐、类风湿关节炎、哮喘、克罗恩病、溃疡性结肠炎、皮炎、季节性过敏性鼻炎、胃食管反流病（GERD）、便秘、腹泻、功能性胃肠障碍、皮肤T细胞淋巴瘤、多发性硬化症、骨关节炎、牛皮癣、系统性红斑狼疮、糖尿病、青光眼、骨质疏松症、肾小球肾炎、肾缺血、肾炎、肝炎、脑中风、血管扩张、高血压、血管炎、心肌梗死、脑缺血、可逆气道阻塞、成人呼吸系统疾病综合征、慢性阻塞性肺疾病（COPD）、隐源性纤维化肺泡炎和支气管炎。
• INDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS
  申请人：Cooymans Ludwig Paul

  公开号：US20130267555A1

  公开（公告）日：2013-10-10

  Indoles having inhibitory activity on RSV replication and having the formula I the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof; compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

  对RSV复制具有抑制活性的吲哚类化合物，具有以下化学式的前药、N-氧化物、加合盐、季铵盐、金属配合物及其立体化异构体形式；包含这些化合物作为活性成分的组合物以及制备这些化合物和组合物的方法。
• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2000066557A1

  公开（公告）日：2000-11-09

  The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

  本发明涉及式(I)的化合物，以及其药学上可接受的盐或溶剂，或这些盐的溶剂，这些化合物抑制羧肽酶U，因此可用于预防和治疗与羧肽酶U相关的疾病。在进一步方面，本发明涉及用于治疗的本发明化合物；制备这些新化合物的过程；包含本发明化合物中至少一种，或其药学上可接受的盐或溶剂的制药组合物，作为活性成分；以及在制造上述医疗用途的药物中使用活性化合物。
• Benzoxazole kinase inhibitors and methods of use
  申请人：Ren Pingda

  公开号：US20100184760A1

  公开（公告）日：2010-07-22

  The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

  本发明提供了一些化学实体或化合物及其制药组合物，这些实体或化合物能够调节某些蛋白激酶，例如mTor、酪氨酸激酶和/或脂质激酶，例如PI3激酶。本发明还提供了使用这些组合物来调节这些激酶中的一个或多个活性的方法，特别是用于治疗应用。